The orphan drug designation is a result of positive findings from a phase 2 clinical trial which demonstrated a 100% clinical benefit rate in patients.
/PRNewswire/ The "Global Respiratory Partnering 2010-2023: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com s offering..